Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors
摘要:
A series of 3,3-disubstituted pyrrolidine monoamine triple reuptake inhibitors were discovered. Analogues with low nanomolar potency, good human in vitro microsomal stability and in vitro permeability, and low drug-drug interaction potential are described. One example showed in vivo anti-depressant-like effects in the mouse tail suspension assay with a minimum effective dose of 30 mg/kg ip. (C) 2008 Elsevier Ltd. All rights reserved.
The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.
[EN] PYRROLIDINYL DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRROLIDINYLE ET LEURS UTILISATIONS
申请人:HOFFMANN LA ROCHE
公开号:WO2009115427A1
公开(公告)日:2009-09-24
The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors.Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.
Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors
作者:Linda M. Bannwart、David S. Carter、Hai-Ying Cai、Jason C. Choy、Robert Greenhouse、Saul Jaime-Figueroa、Pravin S. Iyer、Clara J. Lin、Eun Kyung Lee、Matthew C. Lucas、Stephen M. Lynch、Ann Marie Madera、Amy Moore、Kerem Ozboya、Lubica Raptova、Ralf Roetz、Ryan C. Schoenfeld、Karin Ann Stein、Sandra Steiner、Marzia Villa、Robert J. Weikert、Yansheng Zhai
DOI:10.1016/j.bmcl.2008.10.025
日期:2008.12
A series of 3,3-disubstituted pyrrolidine monoamine triple reuptake inhibitors were discovered. Analogues with low nanomolar potency, good human in vitro microsomal stability and in vitro permeability, and low drug-drug interaction potential are described. One example showed in vivo anti-depressant-like effects in the mouse tail suspension assay with a minimum effective dose of 30 mg/kg ip. (C) 2008 Elsevier Ltd. All rights reserved.